When I began practicing obesity medicine nearly 20 years ago, it was difficult for my patients to attain significant long-term weight loss without metabolic and bariatric surgery.
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid
